In this SOHO Insider roundtable discussion, Charalambos (Babis) Andreadis, MD, MS, professor of clinical medicine at University of California, San Francisco, moderates a discussion on CELLMods in lymphoma.
The panelists include Jason Westin, MD, associate professor in the Department of Lymphoma/Myeloma at University of Texas MD Anderson Cancer Center; Loretta Nastoupil, MD, section chief of indolent lymphoma and director of clinical research at Common Spirit Health; and Swetha Thiruvengadam, MD, assistant clinical professor in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope.
In this video, the group discusses obstacles to adopting golcadomide in community practice for DLBCL, including the need for education on integrating it into existing options like lenalidomide, prioritizing therapies, and its low-dose potency. They note familiarity with lenalidomide may ease adoption, and express optimism for novel combinations to potentially replace chemotherapy.
“I think there’s a need for education because… It’s usually not a list in terms of priorities. So how do you introduce another therapy into that laundry list of options?” Dr. Nastoupil said on community adoption of golcadomide in DLBCL.
Watch more videos from this discussion.
This video is being brought to you by an education grant by Bristol Myers Squibb.
